PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): PROTECT STUDY INTERIM RESULTS

被引：0
|
作者：
Radhakrishnan, Jai [1 ]
Wong, Muh Geot [2 ,3 ]
Heerspink, Hiddo J. L. [4 ]
Komers, Radko [5 ]
Prasad, Andy [5 ]
Mercer, Alex [6 ]
机构：
[1] Columbia Univ, New York, NY USA
[2] Concord Repatriat Gen Hosp, Concord, NSW, Australia
[3] Univ Sydney, Concord Clin Sch, Camperdown, NSW, Australia
[4] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[5] Travere Therapeut Inc, San Diego, CA USA
[6] JAMCO Pharma Consulting, Stockholm, Sweden
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2023年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
329
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [1] SUPERIOR PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): A PROTECT STUDY INTERIM ANALYSIS
    Barratt, Jonathan
    Heerspink, Hiddo Lambers
    Wong, Muh
    Komers, Radko
    Mercer, Alex
    Radhakrishnan, Jai
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I23 - I24
  • [2] Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)
    Busch, Martin
    INNERE MEDIZIN, 2024, 65 : S147 - S148
  • [3] IMPROVING PROTEINURIA WITH SPARSENTAN (SPAR) IN PATIENTS (PTS) WITH IGA NEPHROPATHY (IGAN): A CASE SERIES
    Goshtaseb, Ray R.
    Sarkar, Mrinalini
    Thajudeen, Bijin
    Tse, K. Edmund
    Block, Agness P.
    Oweis, Shadi
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [4] IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
    Barratt, Jonathan
    Rovin, Brad
    Wong, Muh Geot
    Alpers, Charles E.
    Bieler, Stewart
    He, Ping
    Inrig, Jula
    Komers, Radko
    Heerspink, Hiddo J. L.
    Mercer, Alex
    Noronha, Irene L.
    Radhakrishnan, Jai
    Rheault, Michelle N.
    Rote, William
    Trachtman, Howard
    Trimarch, Hernan
    Perkovic, Vlado
    PROTECT Investigators
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (05): : 1043 - 1056
  • [5] Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
    Trachtman, Howard
    Komers, Radko
    Inrig, Jula
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (06) : 571 - 576
  • [6] SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
    Cheung, Chee Kay
    Moody, Stephanie
    Dhaun, Neeraj
    Griffin, Sian
    Howson, Alexandra
    Komers, Radko
    Mercer, Alex
    Sayer, Matthew
    Sinha, Smeeta
    Willcocks, Lisa
    Barratt, Jonathan
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [7] Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study
    Rizk, Dana V.
    Kollins, Dmitrij
    Papachristofi, Olympia
    Hach, Thomas
    Valentin, Marie-Anne
    Merkel, Tobias
    Renfurm, Ronny W.
    Perkovic, Vlado
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [8] Clinical and immunohistochemical study of immunoglobulin A nephropathy (IgAN) before and after tonsillectomy
    Abe, K
    Miyazaki, M
    Shioshita, K
    Harada, T
    Koji, T
    Kohno, S
    ACTA OTO-LARYNGOLOGICA, 2004, 124 : 20 - 24
  • [9] SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL
    Rovin, Brad
    Barratt, Jonathan
    Murphy, Edward
    Geletka, Rob
    Komers, Radko
    Perkovic, Vlado
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S114 - S114
  • [10] MODELLING LONG-TERM OUTCOMES FOR PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN) FROM SHORT-TERM PROTEINURIA DATA
    Bensink, Mark
    Sullivan, Sean
    Zhou, Jenny
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I25 - I26
12345